Replies to post #489185 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

They have a pending trial with the adjuvants and that will likely further improve results, but I would not suggest that it’s not a spectacular result as it is.

[Poor Man -]

The first time I met DI I found him a bit off-putting. But the few times we communicated afterwards, including one lengthy chat, I actually found him fairly accommodating and interesting to speak with.

I think he totally gets everyone’s frustration, and wants to do the right thing; but his hands are tied by his boss. And got the sense they don’t share everything with him either, which can lead to him having some egg on his face.

[danielboog2]

Gary, I was being a bit facetious. The whole crew has a tough job but they need to measure up.

After NYAS/Asco not meeting expectations I really got an outlook of futility with not much on the horizon. I really could not understand NWBO's reluctance to preview a lot of trial info. So this coming presentation in the UW perhaps will unlock a lot of trial embargoed data and projections.

The Journal will exceed all the publicity of these presentations combined....but the "big kahuna" FDA BLA ACCEPTANCE PR